Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

被引：0

作者：

Zhang, Yi ^{[1
]}

Zhou, Hu ^{[2
]}

Suo, Shanshan ^{[1
]}

Zhuang, Junling ^{[3
]}

Yang, Linhua ^{[4
]}

He, Aili ^{[5
]}

Liu, Qingchi ^{[6
]}

Du, Xin ^{[7
]}

Gao, Sujun ^{[8
]}

Li, Yarong ^{[9
]}

Li, Yan ^{[10
]}

Chen, Yuqing ^{[11
]}

Wu, Wen ^{[12
]}

Zhu, Huanling ^{[13
]}

He, Guangsheng ^{[14
]}

Hong, Mei ^{[15
]}

Jiang, Qian ^{[16
]}

Jiang, Zhongxing ^{[17
]}

Jing, Hongmei ^{[18
]}

Wang, Jishi ^{[19
]}

Xu, Na ^{[20
]}

Yue, Lingling ^{[21
]}

Zheng, Cuiping ^{[22
]}

Zhou, Zeping ^{[23
]}

Jin, Chenghao ^{[24
]}

Li, Xin ^{[25
]}

Liu, Lin ^{[26
]}

Xu, Yajing ^{[27
]}

Wu, Dengshu ^{[28
]}

Zhang, Feng ^{[29
]}

Zhang, Jin ^{[30
]}

Xiao, Zhijian ^{[31
]}

Jin, Jie ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China

[2] Henan Prov Hematol Hosp, Dept Hematol, Zhengzhou, Henan, Peoples R China

[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China

[4] Second Hosp Shanxi Med Univ, Neurosurg, Taiyuan, Peoples R China

[5] Xi An Jiao Tong Univ, Dept Neurol, Affiliated Hosp 2, Xian, Peoples R China

[6] Hebei Med Univ, Hosp 1, Shijiazhuang, Peoples R China

[7] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Hematol, Guangzhou, Peoples R China

[8] First Hosp Jilin Univ, Dept Hematol, Changchun, Peoples R China

[9] Second Hosp Jilin Univ, Dept Hematol & Oncol, Changchun, Peoples R China

[10] China Med Univ, Affiliated Hosp 1, Dept Hematopathol, Shenyang, Peoples R China

[11] Henan Prov Peoples Hosp, Dept Hematol, Zhengzhou, Peoples R China

[12] Shanghai Jiao Tong Univ, Shanghai Inst Hematol, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom,Ruijin Hosp,Sch Med, Shanghai, Peoples R China

[13] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China

[14] Nanjing Med Univ, Key Lab Hematol, Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalize,Affiliated, Nanjing, Peoples R China

[15] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China

[16] Peking Univ, Inst Hematol, Natl Clin Res Ctr Hematol Dis, Peoples Hosp, Beijing, Peoples R China

[17] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[18] Peking Univ Third Hosp, Beijing, Peoples R China

[19] GuiZhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang City, Peoples R China

[20] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China

[21] Lanzhou Univ Second Hosp, Dept Hematol & Oncol, Lanzhou, Peoples R China

[22] Wenzhou Cent Hosp, Dept Oncol 2, Wenzhou, Peoples R China

[23] Kunming Med Univ, Affiliated Hosp 2, Kunming, Peoples R China

[24] Jiangxi Prov Peoples Hosp, Nanchang, Peoples R China

[25] Cent South Univ, Third Xiangya Hosp, Dept Hematol, Changsha, Peoples R China

[26] Chongqing Med Univ, Affiliated Hosp 1, Dept Hematol, Chongqing, Peoples R China

[27] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China

[28] Cent South Univ, Xiangya Hosp, Dept Hematol, Changsha, Peoples R China

[29] Bengbu Med Coll, Affiliated Hosp 1, Dept Hematol, Bengbu, Peoples R China

[30] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Hematol, Hangzhou, Peoples R China

[31] Chinese Acad Med Sci & Peking Union Med Coll, MDS & MPN Ctr, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-202790

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3165 / 3166

页数：2

共 50 条

[31] Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
Kivitz, Alan
Sedova, Liliana
Churchill, Melvin
Vizcaya, Cynthia
Sutariya, Reema
Cao, Wenhao
Singhal, Atul
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4750 - 4752
[32] Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
Blons, H.
Emile, J. F.
Le Malicot, K.
Julie, C.
Zaanan, A.
Tabernero, J.
Mini, E.
Folprecht, G.
Van Laethem, J. L.
Thaler, J.
Bridgewater, J.
Norgard-Petersen, L.
Van Cutsem, E.
Lepage, C.
Zawadi, M. A.
Salazar, R.
Laurent-Puig, P.
Taieb, J.
ANNALS OF ONCOLOGY, 2014, 25 (12) : 2378 - 2385
[33] Analysis of empagliflozin vs placebo by Quality and Outcomes Framework targets: post hoc analysis of pooled data from phase III trials
Brice, R.
Hassan, S. W.
Bingham-Gardiner, P.
Crowe, S.
Hach, T.
Salsali, A.
Naderali, E.
DIABETIC MEDICINE, 2015, 32 : 96 - 96
[34] Clinical factors associated with satisfaction of cancer patients for the treatment of opioid-induced constipation: A post hoc analysis utilizing outcomes of naldemedine phase III study
Ishiki, H.
Satomi, E.
Tada, Y.
Yokota, T.
Sato, H.
Okamoto, M.
Osaka, I.
ANNALS OF ONCOLOGY, 2018, 29 : 130 - 130
[35] Association Between Short-Term Change in Quality of Life and Clinical Outcomes: A Post Hoc Analysis of the ISCHEMIA Trial
Caldonazo, Tulio
Kim, Jessica
Heise, Rachel
Rahouma, Mohamed
Harik, Lamia
Redfors, Bjorn
Sandner, Sigrid
Doenst, Torsten
Gaudino, Mario F. L.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (07):
[36] Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial
Koshino, Akihiko
Neuen, Brendon L.
Oshima, Megumi
Toyama, Tadashi
Hara, Akinori
Arnott, Clare
Neal, Bruce
Jardine, Meg
Badve, Sunil, V
Mahaffey, Kenneth W.
Pollock, Carol
Hansen, Michael K.
Wada, Takashi
Heerspink, Hiddo J. L.
KIDNEY INTERNATIONAL REPORTS, 2024, 9 (02): : 347 - 355
[37] Certolizumab Pegol Plasma Concentrations and Endoscopic and Clinical Outcomes in Crohn's Disease: A Post Hoc Analysis of the MUSIC Trial
Sandborn, William
Colombel, Jean-Frederic
Allez, Matthieu
Dupas, Jean-Louis
Dewit, Olivier
D'Haens, Geert
Bouhnik, Yoram
Hebuterne, Xavier
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S674 - S675
[38] ANTIHISTAMINE USE AND STRUCTURAL PROGRESSION OF KNEE OA: A POST-HOC ANALYSIS OF TWO PHASE III CLINICAL TRIALS
Bihlet, A. R.
Miller, C. P.
Byrjalsen, I.
Andersen, J. R.
Karsdal, M.
Baker, M. C.
Rao, T.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 152 - 152
[39] Impact of risankizumab on the duration of PASI90 achievement: A post hoc analysis of 4 phase III clinical trials
Lebwohl, Mark G.
Soliman, Ahmed M.
Yang, Hongbo
Wang, Jessie
Koenigsberg, Sarah H.
Anderson, Annika
Padilla, Bryon
Pinter, Andreas
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB62 - AB62
[40] Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
McInnes, Iain B.
Ferraccioli, Gianfranco
D'Agostino, Maria-Antonietta
Le Bars, Manuela
Banerjee, Subhashis
Ahmad, Harris A.
Elbez, Yedid
Mease, Philip J.
RMD OPEN, 2019, 5 (01):

← 1 2 3 4 5 →